Abstract
Optimal balance between protection from rejection and the adverse consequences of over-immunosuppression is an important unmet need in clinical practice after heart transplant (HT). We tested the clinical utility of Quantiferon monitor (QFM), a novel immune monitoring test, to detect conditions of under-immunosuppression after organ transplantation and identify patients at risk of adverse outcomes.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
